⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8749660 | 1.00 | — | — | |
| SCHEMBL19085875 | 1.00 | — | — | |
| SCHEMBL17858567 | 1.00 | — | — | |
| SCHEMBL6629060 | 1.00 | — | — | |
| SCHEMBL10233235 | 1.00 | — | — | |
| SCHEMBL2609217 | 1.00 | — | — | |
| SCHEMBL12808983 | 1.00 | — | — | |
| SCHEMBL15800362 | 1.00 | — | — | |
| SCHEMBL25038761 | 0.76 | — | — | |
| SCHEMBL6627512 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4142732-B1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250109122-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2025-04-03 | — | — | US | disclosed |
| US-12202817-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240140932-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2024-05-02 | — | — | US | disclosed |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-07-20 | — | — | US | disclosed |
| EP-4142732-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| EP-4143178-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20220396562-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2022-12-15 | — | — | US | disclosed |
| WO-2022115879-A1 | PYRROLIDINE DERIVATIVES AND METHODS OF USE | GENENTECH, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-20160222015-A1 | TRICYCLIC GYRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-08-04 | — | — | US | disclosed |
| US-20160096827-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2016-04-07 | — | — | US | disclosed |
| WO-2016049211-A1 | AMINOTRIAZINE DERIVATIVES USEFUL AS TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2016-03-31 | — | — | WO | disclosed |
| US-20150218146-A1 | SUBSTITUTED OXINDOLE DERIVATIVES, MEDICAMENTS CONTAINING SAID DERIVATIVES AND USE THEREOF | ABBVIE DEUTSCHLAND (DE) | 2015-08-06 | — | — | US | disclosed |
| US-20140221332-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2014-08-07 | — | — | US | disclosed |
| EP-2323980-B1 | 7-(PIPERAZINE-1-YMETHYL)-1H-INDOLE-2-CARBOXYLIC ACID (PHENYL)-AMIDE DERIVATIVES AND ALLIED COMPOUNDS AS P38 MAP KINASE INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2012-02-29 | — | — | EP | disclosed |
| US-8044079-B2 | Substituted oxindole derivatives, medicaments containing said derivatives and use thereof | ABBOTT GMBH & CO. KG (DE) | 2011-10-25 | — | — | US | disclosed |
| US-20100273766-A1 | SUBSTITUTED OXINDOL DERIVATIVES, MEDICAMENTS CONTAINING SAID DERIVATIVES AND USE THEREOF | ABBOTT GMBH & CO. KG (DE) | 2010-10-28 | — | — | US | disclosed |
| US-7659305-B2 | 4-carbo- or heterocyclic alkyl-, oxy-, amino-, and thio-substituted; e.g., 2S, 4S)-4-(3-Chloro-phenoxy)-pyrrolidine-2-carboxylic acid; controlling neurotransmitter release; uses include general treatment of pain, particularly neuropathic pain. | PFIZER INC. (US) | 2010-02-09 | — | — | US | disclosed |
| WO-2005002577-A1 | DUAL NK1/NK3 ANTAGONISTS FOR TREATING SCHIZOPHRENIA | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-13 | — | — | WO | disclosed |